These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Discrimination between growth hormone (GH) deficiency of hypothalamic or pituitary origin: an aid in selecting patients for GH-releasing hormone (RH) prolonged therapy.
    Author: Keret R, Josefsberg Z, Kinarti H, Silbergeld A, Szoke B, Schally AV, Laron Z.
    Journal: Isr J Med Sci; 1988; 24(4-5):207-11. PubMed ID: 3132434.
    Abstract:
    Eleven patients with GH deficiency (GHD) underwent i.v. GH-RH tests (1 mu/kg); 7 had idiopathic GH deficiency (IGHD) and 4 had multiple pituitary hormone deficiencies (MPHD)--diagnosed on the basis of the insulin hypoglycemia, clonidine and sleep tests. One test was done before and the other after five s.c. injections of 1 microgram/kg GH-RH given in the evening. There were three types of response: four patients in whom there was an increase of human GH (hGH) to twice the former level, from 11.6 +/- 4.9 to 22.8 +/- 7.3 ng/ml following priming (a partial hypothalamic lesion); five patients in whom there was no response to the pharmacological tests but the same rise of approximately 13 ng/ml in hGH in response in both acute GH-RH tests (partial pituitary lesion); and two patients with no response to the pharmacological and acute GH-RH tests (pituitary lesion). In all except one patient there was no change in the serum IGF-I values after 5 days priming with GH-RH. It is suggested that patients with a partial GHD due to a hypothalamic lesion might benefit from long-term therapy with GH-RH.
    [Abstract] [Full Text] [Related] [New Search]